This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
by Zacks Equity Research
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
by Zacks Equity Research
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
by Zacks Equity Research
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
by Zacks Equity Research
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
Here's Why Merck (MRK) Gained But Lagged the Market Today
by Zacks Equity Research
Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
by Zacks Equity Research
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
by Zacks Equity Research
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
by Zacks Equity Research
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
by Zacks Equity Research
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck (MRK) Stock Moves -0.63%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $117.84, moving -0.63% from the previous trading session.
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
by Kinjel Shah
European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
by Zacks Equity Research
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
by Zacks Equity Research
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
by Zacks Equity Research
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
Merck (MRK) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
by Zacks Equity Research
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
by Kinjel Shah
LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
by Zacks Equity Research
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
by Zacks Equity Research
MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
Do Options Traders Know Something About Merck (MRK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.
The Zacks Analyst Blog Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of Distinction
by Zacks Equity Research
Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of Distinction are included in this Analyst Blog.